Interestingly, CX‐4945, a CK2 inhibitor targeting p‐MYH9, and S02, a USP22 inhibitor, were shown to effectively reverse lenvatinib resistance in HCC cells, presenting a novel therapeutic strategy for lenvatinib‐resistant HCC patients.[31]. Here, USP22 is linked to hepatocellular carcinoma.